Zalgen Antibodies Used in Solving First Lassa Virus Glycoprotein Trimer Structure
Article in Science provides template for advanced vaccine and immunotherapeutic design against Lassa Fever, a major threat to global health Zalgen Labs LLC (Zalgen), a biotechnology and diagnostics company focused on high-impact, neglected infectious diseases including Lassa Fever (LF), today announced that its human monoclonal antibodies were used in an extensive research collaboration of the […]
Zalgen Antibodies Used in Solving First Lassa Virus Glycoprotein Trimer Structure Read More »
